Genetic insights into sepsis: What have we learned and how will it help?

Current Pharmaceutical Design

Volumn 14, Issue 19, 2008, Pages 1900-1911

  Wurfel, M M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Genetic; Inflammation; Innate immune; Polymorphism; Sepsis; Susceptibility

Indexed keywords

ADAPTOR PROTEIN; ANTIINFECTIVE AGENT; BACTERICIDAL PERMEABILITY INCREASING PROTEIN; CD14 ANTIGEN; GENE PRODUCT; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 4; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; LIPOPROTEIN; LYMPHOTOXIN; MANNOSE BINDING LECTIN; MANNOSE BINDING LECTIN 2; MYELOID DIFFERENTIATION FACTOR 88; NUCLEIC ACID; PROTEIN MD 2; PROTEIN TIRAP; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SIGNAL PEPTIDE; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR ANTAGONIST; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADULT RESPIRATORY DISTRESS SYNDROME; BLOOD CLOTTING; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CRITICALLY ILL PATIENT; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; GENE LINKAGE DISEQUILIBRIUM; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HEALTH CARE COST; HUMAN; INFECTION RISK; INNATE IMMUNITY; INTENSIVE CARE UNIT; MENINGOCOCCEMIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RACE DIFFERENCE; REVIEW; SEPSIS; SEPTIC SHOCK; SINGLE NUCLEOTIDE POLYMORPHISM; VARIABLE NUMBER OF TANDEM REPEAT;

ANIMALS; CLINICAL TRIALS AS TOPIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNITY, NATURAL; INFLAMMATION MEDIATORS; INTENSIVE CARE UNITS; SEPSIS; SHOCK, SEPTIC; VARIATION (GENETICS);

EID: 48249115536     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784980554     Document Type: Review

References (137)

1. Hotchkiss, RS, Karl, IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50.
2. Sorensen TI, Nielsen GG, Andersen PK, Teasdale TW. Genetic and environmental influences on premature death in adult adoptees. N Engl J Med 1988; 318: 727-32.
3. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang Y, et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 2003; 299: 2076-9.
4. International Human Genome Consortium. Finishing the euchromatic sequence of the human genome. Nature 2004; 431: 931-45.
5. Crawford DC, Akey DT, Nickerson DA. The patterns of natural variation in human genes. Annu Rev Genomics Hum Genet 2005; 6: 287-312.
6. Feuk L, Marshall CR, Wintle RF, Scherer SW. Structural variants: changing the landscape of chromosomes and design of disease studies. Hum Mol Genet 2006; 15(Spec No 1): R57-66.
7. Tuzun E, Sharp AJ, Bailey JA, Kaul R, Morrison VA, Pertz LM, et al. Fine-scale structural variation of the human genome. Nat Genet 2005; 37: 727-32.
8. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature 2006; 444: 444-54.
9. A haplorype map of the human genome. Nature 2005; 437: 1299-320.
10. Pritchard JK, Rosenberg NA. Use of unlinked genetic makers to detect population stratification in association studies. Am J Hum Genet 1999; 65: 220-8.
11. Russell JA. Management of sepsis. N Engl J Med 2006; 355: 1699-713.
12. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
13. O'Neill LA, Bowie AG. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 2007; 7: 353-64.
14. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/ tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-71.
15. Taveira da Silva AM, Kaulbach HC, Chuidian FS, Lambert DR, Suffredim AF, Danner RL. Brief report: Shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N Engl J Med 1993; 328: 1457-60.
16. Poltorak A, He X, Smirnova I, Liu MY, Huffel CV, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science 1998; 282: 2085-8.
17. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M, et al. Lipopolysaccharide (LPS)-bindmg protein accelerates the binding of LPS to CD14. J Exp Med 1994; 179: 269-77.
18. Yu B, Wright SD. Catalytic properties of lipopolysaccharide (LPS) binding protein. Transfer of LPS to soluble CD14. J Biol Chem 1996; 271: 4100-5.
19. Weiss J. Bactericidal/permeability-inereasing protein (BPI) and lipopolysaccharide-binding protein (LBP): Structure, function and regulation in host defence against Gram-negative bacteria. Biochem Soc Trans 2003; 31: 785-90.
20. Branger J, Knapp S, Weijer S, Leemans JC, Pater JM, Speelman P, et al. Role of Toll-like receptor 4 in gram-positive and gram-negative pneumonia in mice. Infect Immun 2004; 72: 788-94.
21. Knapp S, Wieland CW, Florquin S, Pantophlet R, Dijkshoom L, Tshimbalanga N, et al. Differential roles of CD14 and toll-like receptors 4 and 2 in murine Acinetobacter pneumonia. Am J Respir Crit Care Med 2006; 173: 122-9.
22. Wieland CW, Florquin S, Maris NA, Hoebe K, Beirtler B, Takeda K, Akira S, et al. The MyD88-dependent but not the MyD88-independent pathway of TLR4 signaling is important in clearing nontypeable haemophilus influenzae from the mouse lung. J Immunol 2005; 175: 6042-9.
23. Branger J, Florquin S, Knapp S, Leemans JC, Pater JM, Speelman P, et al. LPS-binding protein-deficient mice have an impaired defense against Gram-negative but not Gram-positive pneumonia. Int Immunol 2004; 16: 1605-11.
24. Kurt-Jones EA, Popova L, Kwinn L, Haynes LK Jones LP, Tripp RA, Walsh EE, et al. Pattern recognition receptors TLR4 and CD 14 mediate response to respiratory syncytial virus. Nat Immunol 2000; 1: 398-401
25. Dessing MC, Knapp S, Florquin S, de Vos AF, van der Poll T. CD14 facilitates invasive respiratory tract infection by Streptococcus pneumoniae. Am J Respir Crit Care Med 2007; 175: 604-11.
26. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25: 187-91.
27. Tuliç MK, Hurrelbrink RJ, Prele CK Laing IA, Upham JW, Le Souef P, et al. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J Immunol 2007; 179: 132-40.
28. Imahara SD, Jelacic S, Junker CE, O'Keefe GE. The TLR4 +896 polymorphism is not associated with lipopolysaccharide hypo-responsiveness in leukocytes. Genes Immun 2005; 6: 37-43.
29. Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299GIy and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp 2003; 197: 1787-91
30. von Aulock S, Schroder NW, Gueinzius K, Traub S, Hoffmann S, Graf K, et al. Heterozygous toll-like receptor 4 polymorphism does not influence lipopolysoccharide-induced cytokine release in human whole blood. J Infect Dis 2003; 188: 938-43.
31. Lorenz E, Mira JP, Frees KL, Schwartz DA. Relevance of Mutations in the TLR4 Receptor in Patients With Gram-Negative Septic Shock. Arch Intern Med 2002; 162: 1028-32.
32. Agnese DM, Calvano JE, Hahm SJ, Coyle SM, Corbett SA, Calvano SE, et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of gram-negative infections. J Infect Dis 2002; 186: 1522-5.
33. Barber RC, Aragaii~CC, Rivera-Chavez FA, Purdue GF, Hunt JL, Horton JW. TLR4 and TNF4pha polymorphisms are associated with an increased risk for severe sepsis following burn injury. J Med Genet 2004; 41: 808-13.
34. Rivem-Chavez FA, Peters-Hybki DL, Barber RC, Lindberg GM, Jialal I, Munford RS, et al. Innate immunity genes influence the severity of acute appendicitis. Ann Surg 2004; 240: 269-77.
35. Read RC, Pullin J, Gregory S, Borrow R, Kaczmarski EB, di Giovine FS, et al. A functional polymorphism of toll-like receptor 4 is not associated with likelihood or severity of meningococcal disease. J Infect Dis 2001; 184: 640-2.
36. Yuan FF, Marks K, Wong M, Watson S, de Leon E, McIntyre PB, et al. Clinical relevance of TLR2, TLR4, CD14 and FcgammaRIIA gene polymorphisms in Streptococcus pneumoniae infection. Immunol Cell Biol 2008; 86(3): 268-70.
37. Hawn TR, Verbon A, Janer M, Zhao LP, Beutler B, Aderem A. Toll-like receptor 4 polymorphisms are associated with resistance to Legionnaires' disease. Proc Natl Acad Sci USA 2005; 102: 2487-9.
38. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD. A Polymorphism* in the 5′ flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. Am J Respir Cell Mol Biol 1999; 20: 976-83.
39. Gao PS, Mao XQ, Baldini M, Roberts MH, Adra CN, Shirakawa T, et al. Serum total IgE levels and CD14 on chromosome 5q311. Clin Genet 1999; 56: 164-5.
40. LeVan TD, Bloom JW, Bailey TJ, Karp CL, Halonen M, Martinez FD, et al. A common single nucleotide polymorphism in the CD14 promoter decreases the affinity of Sp protein binding and enhances transcriptional activity. J Immunol 2001; 167: 5838-44.
41. Lin J, Yao YM, Yu Y, Chai JY, Huang ZH, Dong N, et al. Effects of CD14-159 C/T polymorphism on CD14 expression and the balance between proinflammatory and anti-iflammatory cytokines in whole blood culture. Shock 2007; 28: 148-53.
42. Gibot S, Cariou A, Drouet L, Rossignol M, Ripoll L. Association between a genomic polymorphism within the CD14 locus and septic shock susceptibility and mortality rate. Crit Care Med 2002; 30: 969-73.
43. Sutherland AM, Walley KR, Russell JA. Polymorphisms in CD14, mannose-binding lectin, and Toll-like receptor-2 are associated with increased prevalence of infection in critically ill adults. Crit Care Med 2005; 33: 638-44.
44. Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Rothe G, et al. The common functional C(-159)T polymorphism within the promoter region of the lipopolysaccharide receptor CD14 is not associated with sepsis development or mortality. Genes Immun 2000; 1: 405-7.
45. Jessen KK Lindboe SB, Petersen AL, Eugen-Olsen J, Benfield T. Common TNF-alpha, IL-1 beta, PAI-1, uPA, CD14 and TLR4 polymorphisms are not associated with disease severity or outcome from Gram negative sepsis. BMC Infect Dis 2007; 7: 108.
46. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999; 189: 1777-82.
47. Dziarski R, Wang Q, Miyake K, Kirschning CJ, Gupta D. MD-2 enables Toll-like receptor 2 (TLR2)-mediated responses to lipopolysaccharide and enhances TLR2-mediated responses to Gram-positive and Gram-negative bacteria and their cell wall components. J Immunol 2001; 166: 1938-44
48. Gu W, Shan YA, Zhou J, Jiang DP, Zhang L, Du DY, et al. Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2. Ann Surg 2007; 246: 151-9.
49. Chien JW, Boeckh, Hansen JA, Clark JG. Lipopolysaccharide binding protein promoter variants influence the risk for Gram-negative bacteremia and mortality after allogeneic hematopoietic cell transplantation. Blood 2008; 111: 2462-9.
50. Barber RC, O'Keefe GE. Characterization of a single nucleotide polymorphism in the lipopolysaccharide binding protein and its association with sepsis. Am J Respir Crit Care Med 2003; 167: 1316-20
51. Hubacek JA, Stuber F, Frohlich D, Book M, Wetegrove S, Ritter M, et al. Gene variants of the bactericidal/permeability increasing protein and lipopolysaccharide binding protein in sepsis patients: gender-specific genetic predisposition to sepsis. Crit Care Med 2001; 129: 557-61.
52. Michalek J, Svedikova P, Fedora K Klimovic M, Klapacova L, Bartosova D, et al. Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med 2007; 33: 2158-64.
53. Medvedev AE, Lentschat A, Kuhns DB, Blanco JC, Salkowski C, Zhang S, et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J Exp Med 2003; 198. 521-31.
54. Lorenz E, Mira JP, Cormish KL, Arbour NC, Schwartz DA. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect Immun 2000; 68: 6398-401.
55. Ogus AC, Yoldas B, Ozdemir T, Uguz A, Olcen S, Keser I, et al. The Arg753GLn polymorphism of the human toll-like receptor 2 gene in tuberculosis disease. Eur Respir J 2004; 23: 219-23.
56. Moore CE, Segal S, Berendt AR, Hill AV, Day NP. Lack of association between Toll-like receptor 2 polymorphisms and susceptibility to severe disease caused by Staphylococcus aureus. Clin Diagn Lab Immunol 2004; 11: 1194-7.
57. Hawn TR, Misch EA, Dunstan SJ, Thwaites GE, Lan NT, Quy HT, et al. A common human TLR1 polymorphism regulates the innate immune response to lipopeptides. Eur J Immunol 2007; 37: 2280-9.
58. Johnson CM, Lyle EA, Omueti KO, Stepensky VA, Yegin O, Alpsoy E, et al. Cutting edge: A common polymorphism impairs cell surface trafficking and functional responses of TLR1 but protects against leprosy. J Immunol 2007; 178: 7520-4.
59. Kesh S, Mensah NY, Peterlongo P, Jaffe D, Hsu K, M VDB, et al. TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 2005; 1062: 95-103.
60. Suzuki N, Suzuki S, Yeh WC. IRAK-4 as the central TIR signaling mediator in innate immunity. Trends Immunol 2002; 23: 503-6.
61. Ku CL, von Bernuth H, Picard C, Zhang SY, Chang HH, Yang K, et al. Selective predisposition to bacterial infections in IRAK-4-deficient children: IRAK-4-dependent TLRs are otherwise redundant in protective immunity. J Exp Med 2007; 204: 2407-22.
62. Swantek JL, Tsen MF, Cobb MH, Thomas JA. IL-1 receptor-associated kinase modulates host responsiveness to endotoxin. J Immunol 2000; 164: 4301-6.
63. Uematsu S, Sato S, Yamamoto M, Hirotani T, Kato H, Takeshita F, et al. Interleukin-1 receptor-associated kinase-1 plays an essential role for Toll-like receptor (TLR)7- and TLR9-mediated interferon-{alpha} induction. J Exp Med 2005; 201: 915-23.
64. Arcaroli J, Silva E, Maloney JP, He Q, Svetkauskaite D, Murphy JR, et al. Variant IRAK-1 haplotype is associated with increased nuclear factor-kappaB activation and worse outcomes in sepsis. Am J Respir Crit Care Med 2006; 173: 1335-41.
65. Fitzgerald KA, Palsson-McDermott EM, Bowie AG, Jefferies CA, Mansell AS, Brady G, et al. Mal (MyD88-adapter-like) is required for Toll-like receptor-4 signal transduction. Nature 2001; 413: 78-83.
66. Horng T, Barton GM, Medzhitov R. TIRAP: An adapter molecule in the Toll signaling pathway. Nat Immunol 2001; 2: 835-41.
67. Jeyaseelan S, Manzer R, Young SK, Yamamoto M, Akira S, Mason RJ, et al. Toll-IL-1 receptor domain-containing adaptor protein is critical for early lung immune responses against Escherichia coli lipopolysaccharide and viable Escherichia coli. J Immunol 2005; 175: 7484-95.
68. Jeyaseelan S, Young SK, Vamamoto M, Arndt PG, Akira S, Kolls JK, et al. Toll/IL-1R domain-containing adaptor protein (TIRAP) is a critical mediator of antibacterial defense in the lung against Klebsiella pneumoniae but not Pseudomonas aeruginosa. J Immunol 2006; 177: 538-47.
69. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007; 39: 523-8.
70. Fraser IP, Koziel H, Ezekowitz RA. The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity. Semin Immunol 1998; 10: 363-72.
71. Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991; 337: 1569-70.
72. Wallis R, Cheng JY. Molecular defects in variant forms of mannose-binding protein associated with immunodeficiency. J Immunol 1999; 163: 4953-9.
73. Garred P, Larsen F, Seyfarth J, Fujita R, Madsen HO. Mannose-binding lectin and its genetic variants. Genes Immun 2006; 7: 85-94.
74. Madsen HO, Garred P, Thiel S, Kurtzhals JA, Lamm LU, Ryder LP, et al. Interplay between promoter and structural gene variants control basal serum level of mannan-binding protein. J Immunol 1995; 155: 3013-20.
75. Naito H, Ikeda A, Hasegawa K, Oka S, Uemura K, Kawasaki N, et al. Characterization of human serum mannan-binding protein promoter. J Biochem 1999; 126: 1004-12.
76. Gordon AC, Waheed U, Hansen TK, Hitman GA, Garrard CS, Turner MW, et al. Mannose-binding lectin polymorphisms in severe sepsis: relationship to levels, incidence, and outcome. Shock 2006; 25: 88-93
77. Garred P, J JS, Quist L, Taaning E, Madsen HO. Association of mannose-binding lectin polymorphisms with sepsis and fatal outcome, in patients vnth systemic inflammatory response syndrome. J Infect Dis 2003; 188: 1394-403.
78. Gong MN, Zhou W, Williams PL, Thompson BT, Pothier L, Christiani DC. Polymorphisms in the mannose binding lectin-2 gene and acute respiratory distress syndrome. Crit Care Med 2007; 35: 48-56.
79. Abraham E, Laterre PF, Garbino J, Pingleton S, Butler T, Dugernier T, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med 2001; 29: 503-10.
80. Reinhart K, Menges T, Gardlund B, Harm Zwaveling J, Smithes M, Vincent JL, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyper-inflammatory response during severe sepsis: The RAMSES Study. Crit Care Med 2001; 29: 765-9.
81. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94: 3195-9.
82. Louis E, Franchimont D, Piron A, Gevaert Y, Schaaf-Lafontaine N, Roland S, et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998; 113: 401-6.
83. Heesen M, Kunz D, Bachmann-Mennenga B, Merk HF, Bloemeke B. Linkage disequilibrium between tumor necrosis factor (TNF)-alpha-308 G/A promoter and TNF-beta Ncol polymorphisms: Association with TNF-alpha response of granulocytes to endotoxin stimulation. Crit Care Med 2003; 31: 211-4.
84. Stuber F, Udalova IA, Book M, Drutskaya IN, Kuprash DV, Turetskaya RL, et al. -308 tumor necrosis factor (TNF) polymorphism is not associated with survival in severe sepsis and is unrelated to lipopolysaccharide inducibility of the human TNF promoter. J Inflamm 1995; 46: 42-50.
85. Kovar FM, Marsik C, Cvitko T, Wagner OF, Jilma B, Endler G. The tumor necrosis factor alpha -308 G/A polymorphism does not influence inflammation and coagulation response in human endotoxemia. Shock 2007; 27: 238-41.
86. Messer G, Spengler U, Jung MC, Honold G, Blomer K, Pape GR, et al. Polymorphic structure of the tumor necrosis factor (TNF) locus: An Ncol polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med 1991; 173: 209-19.
87. Ozaki K, Ohnishi Y, Iida A, Sekine A, Yamada R, Tsunoda T, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-4.
88. Knight JC, Keating BJ, Kwiatkowski DP. Allele-specific repression of lymphotoxin-alpha by activated B cell factor-1. Nat Genet 2004; 36: 394-9.
89. Whichelow CE, Hitman GA, Raafat I, Bonazzo GF, Sachs JA. The effect of TNF*B gene polymorphism on TNF-alpha and -beta secretion levels in patients with insulin-dependent diabetes mellitus and healthy controls. Eur J Immunogenet 1996; 23: 425-35.
90. Mira JP, Cariou A, Grall F, Delclaux C, Losser MR, Heshmati F, et al. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study. JAMA 1999; 282: 561-8.
91. Nakada TA, Hirasawa H, Oda S, Shiga H, Matsuda K, Nakamura M, et al. Influence of toll-like receptor 4, CD14, tumor necrosis factor, and interleukine-10 gene polymorphisms on clinical outcome in Japanese critically ill patients. J Surg Res 2005; 129: 322-8.
92. Waterer GW, Quasney MW, Cantor RM, Wunderink RG. Septic shock and respiratory failure in community-acquired pneumonia have different TNF polymorphism associations. Am J Respir Crit Care Med 200 1; 163: 1599-604.
93. Gordon AC, Lagan AL, Aganna E, Cheung L, Peters CJ, McDermott MF, et al. TNF and TNFR polymorphisms in severe sepsis and septic shock: A prospective multicentre study. Genes Immun 2004; 5: 631-40.
94. Struber F, Petersen M, Bokelmann F, Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996; 24: 381-4.
95. Majetschak M, Flohe S, Obertacke U, Schroder J, Staubach K, Nast-Kolb D, et al. Relation of a TNF gene polymorphisin to severe sepsis in trauma patients. Ann Surg 1999; 230: 207-14.
96. Rauchschwalbe SK, Maseizik T, Mittelkotter U, Schluter B, Patzig C, Thiede A, et al. Effect of the LT-alpha (+250 G/A) polymorphism on markers of inflammation and clinical outcome in critically ill patients. J Trauma 2004; 56: 815-22.
97. Schaaf BM, Boehmke F, Esnaashari H, Seitzer U, Kothe H, Maass M, et al. Pneumococcal septic shock is associated with the interleukin-10-1082 gene promoter polymorphism. Am J Respir Crit Care Med 2003; 168: 476-80.
98. Rivera-Chavez FA, Peters-Hybki DL, Barber RC, O'Keefe GE. Interleukin-6 promoter haplotypes and interleukin-6 cytokine responses. Shock 2003; 20: 218-23.
99. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, Humphries S, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 1998; 102: 1369-76.
100. Heesen M, Obertacke U, Schade FU, Bloemeke B, Majetschak M. The interleukin-6 G(-174)C polymorphism and the ex vivo interleukin-6 response to endotoxin in severely injured blunt trauma patients. Eur Cytokine Netw 2002; 13: 72-7.
101. Tischendorf JJ, Yagmur E, Scholten D, Vidacek D, Koch A, Winograd R, et al. The interleukin-6 (IL6)-174 G/C promoter genotype is associated with the presence of septic shock and the ex vivo secretion of IL6. Int J Immunogenet 2007; 34: 413-8.
102. Schluter B, Raufhake C, Effen M, Schotte H, Kipp F, Rust S, et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med 2002; 30: 32-7.
103. Schaaf B, Rupp J, Muller-Steinhardt M, Kruse J, Boehmke F, Maass M, et al. The interleukin-6 -174 promoter polymorphism is associated with extrapulmonary bacterial dissemination in Streptococcus pneumoniae infection. Cytokine 2005; 31: 324-8.
104. Gallagher PM, Lowe G, Fitzgerald T, Bella A, Greene CM, McElvaney NG, et al. Association of IL-10 polymorphism with severity of illness in community acquired pneumonia. Thorax 2003; 58: 154-6.
105. Sutherland AM, Walley KT, Manocha S, Russell JA. The association of interleukin 6 haplolype clades with mortality in critically ill adults. Arch Intern Med 2005; 165: 75-82.
106. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: Results of the Genetic and Inflammatory Markers of Sepsis (GenIMS). Study Arch Intern Med 2007; 167: 1655-63.
107. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995; 63: 2109-12.
108. Wurfel MM, Park WY, Radella F, Ruzinski J, Sandstrom A, Strout J, et al. Identification of high and low responders to lipopolysaccharide in normal subjects: An unbiased approach to identify modulators of innate immunity. J Immunol 2005; 175: 2570-8.
109. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T. Differential regulation of interleukin-10 production by genetic and environmental factors - a twin study. Genes Immun 2002; 3: 407-13.
110. Schippers EF, van't Veer C, van Voorden S, Martina CA, Huizinga TW, le Cessie S, et al. IL-10 and toll-like receptor-4 polymorphisms and the in vivo and ex vivo response to endotoxin. Cytokine 2005; 29: 215-28.
111. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. Polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum 1999; 42: 1101-8.
112. Wattanathum A, Manocha S, Groshaus H, Russell JA, Walley KR. Interleukin-10 haplotype associated with increased mortality in critically ill patients with sepsis from pneumonia but not in patients with extrapulmonary sepsis. Chest 2005; 128: 1690-8.
113. Gong MN, Thompson BT, Williams PL, Zhou W, Wang MZ, Pothier L, et al. Interleukin-10 polymorphism in position -1082 and acute respiratory distress syndrome. Eur Respir J 2006; 27: 674-81.
114. Witkin SS, Gerber S, Ledger WJ. Influence of interleukin-1 receptor antagonist gene polymorphism on disease. Clin Infect Dis 2002; 34: 204-9.
115. Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995; 99: 303-10.
116. Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998; 28: 2598-602.
117. Fang XM, Schroder S, Hoeft A, Stuber F. Comparison of two polymorphisms of the interleukin-1 gene family: Interleukin-1 receptor antagonist polymorphism contributes to susceptibility to severe sepsis. Crit Care Med 1999; 27: 1330-4.
118. Ma P, Chen D, Pan J, Du B. Genomic polymorphism within interleukin-1 family cytokines influences the outcome of septic patients. Crit Care Med 2002; 30: 1046-50.
119. Arnalich F, Lopez-Maderuelo D, Codocco R, Lopez J, Solis-Garrido LM, Capiscol C, et al. Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002; 127: 331-6.
120. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-45.
121. Eriksson P, Kallin B, van 't Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
122. Haralambous E, Hibberd ML, Hermans PW, Ninis N, Nadel S, Levin M. Role of functional plasminogen-activator-inhibitor-1 4G/5G promoter polymorphism in susceptibility, severity, and outcome of meningococcal disease in Caucasian children. Crit Care Med 2003; 31: 2788-93.
123. Geishofer G, Binder A, Muller M, Zohrer B, Resch B, Muller W, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene in children with systemic meningococcaemia. Eur J Pediatr 2005; 164: 486-90.
124. Hermans PW, Hibberd ML, Booy R, Daramola O, Hazelzet JA, de Groot R, et al. 4G/5G promoter polymorphism in the plasminogen-activator-inhibitor-1 gene and outcome of meningococcal disease. Meningococcal Research Group. Lancet 1999; 354: 556-60.
125. Garcia-Segarra G, Espinosa G, Tassies D, Oriola J, Aibar J, Bove A, et al. Increased mortality in septic shock with the 4G/4G geno-type of plasminogen activator inhibitor 1 in patients of white descent. Intensive Care Med 2007; 33: 1354-62.
126. Benfield TL, Dahl M, Nordestgaard BG, Tybjaerg-Hansen A. Influence of the factor V Leiden mutation on infectious disease susceptibility and outcome: A population-based study. J Infect Dis 2005; 192: 1851-7.
127. Walley KR, Russell JA. Protein C -1641 AA is associated with decreased survival and more organ dysfunction in severe sepsis. Crit Care Med 2007; 35: 12-7.
128. Smirnova I, Hamblin MT, McBride C, Beutler B, Di Rienzo A. Excess of rare amino acid polymorphisms in the Toll-like receptor 4 in humans. Genetics 2001; 158: 1657-64.
129. Zheng SL, Sun J, Wiklund F, Smith S, Stattin P, Li G, et al. Cumulative association of five genetic variants with prostate cancer. N Engl J Med 2008; 358: 910-9.
130. Fisher CJ Jr., Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43.
131. Opal SM, Fisher CJ, Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 1997; 25: 1115-24.
132. Mathew CG. New links to the pathogenesis of Crohn disease provided by genome-wide association scans. Nat Rev Genet 2008; 9: 9-14.
133. Moffatt MF, Kabesch M, Liang L, Dixon AL, Strachan D, Heath S, et al. Genetic variants regulating ORMDL3 expression contribute to the risk of childhood asthma. Nature 2007; 448: 470-3.
134. Saxena R, Voight BF, Lyssenko V, Burtt NP, de Bakker PI, Chen H, et al. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science 2007; 316, 1331-6.
135. Candore G, Balistreri CR, Caruso M, Grimaldi MP, Incalcaterra E, Listi F, et al. Pharmacogenomics: A tool to prevent and cure coronary heart disease. Curr Pharm Des 2007; 13(36): 3726-34.
136. Castellon R, Hamdi HK. Demystifying the ACE polymorphism: From genetics to biology. Curr Pharm Des 2007; 13(12): 1191-8.
137. Vandel P, Talon J. M, Haffen E, Sechter D. Pharmacogenetics and drug therapy in psychiatry - the role of the CYP2D6 polymorphism. Curr Pharm Des 2007; 13(2): 241-50.